Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comparison of effectiveness of Liposomal Cisplatin combined with Paclitaxel versus Cisplatin combined with Paclitaxel in patients with adenocarcinoma and undifferentiated carcinoma of the lungs.

Next Previous
Trial Profile

Comparison of effectiveness of Liposomal Cisplatin combined with Paclitaxel versus Cisplatin combined with Paclitaxel in patients with adenocarcinoma and undifferentiated carcinoma of the lungs.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 13 Jul 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cisplatin (Primary) ; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 08 Jul 2011 Additional primary endpoints added as reported by Australian New Zealand Clinical Trials Registry.
  • 08 Jul 2011 New source added and integrated (ACTRN12610000046000, Australian New Zealand Clinical Trials Registry).
  • 08 Jul 2011 Actual initiation date (Sep 2007) added as reported by Australian New Zealand Clinical Trials Registry.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top